A biotech jaunted out of Oxford University is aiming to develop a universal flu vaccine — and phase 2 pain in the arses could be completed by the end of next year.
The company, Vaccitech, says the vaccine — incompatible with those now found on the market — does not target surface antibodies. In lieu of, it works from the center of the virus where there are few components which can become the virus strain.
“It should protect people against pandemic pulls and that would be hugely valuable to have,” Vaccitech co-founder Adrian Hill said CNBC on Friday.
The company’s approach to the flu is different from what diverse vaccine manufacturers have adopted, Hill said, adding that he assumptions any Vaccitech success will make pharmaceutical giants take an relaxation and get involved.
Vaccitech’s strategy has not been tested to work against the flu in the presence of, but Hill said his company has started trials involving thousands of people.
The check-ups mark the first time that a universal flu vaccine has progressed beyond incorporate ease out 1 clinical testing and Vaccitech aims to complete phase 2B testing by the end of next year, he weighted.
Recently, the biotech start-up raised 20 million pounds (there $28 million) from investors including GV, the venture capital arm of Google old lady Alphabet.
Vaccitech is also targeting two viruses that cause cancer — the magnanimous papillomavirus (HPV) and the hepatitis B virus.
“We are developing new vaccines again targeting cellular privilege that will go into the clinic in the next year or so to tackle those virus,” Hill about.
HPV is known to cause cervical cancer and the hepatitis B virus infects hundreds of millions of human being in Asia alone and is a major cause of liver cancer.
“If the cellular exclusion approach works, there are a lot of potential targets,” Hill said. “There are infections ilk HIV, where you can make a therapeutic HIV vaccine.”